Special Issue "Kinase Inhibitor Chemistry"
Deadline for manuscript submissions: closed (15 August 2016)
The development of therapeutic agents that target the inhibition of kinases has proven to be a fruitful endeavor. More than two dozen agents have been approved by the U. S. FDA in the last fifteen years. While there is no longer a question as to whether kinases are valid targets, there are still a myriad of approaches for pursuing inhibitors that span selectivity and reversibility parameters. Additionally, the utility of kinase inhibitors has been demonstrated in a variety of indications, from cancer to inflammation and pulmonary disease. This Special Issue aims to highlight recent results in the identification and optimization of kinase inhibitors in the continued search for new medicinal agents.
Professor James W. Leahy
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- kinase inhibitor
- drug discovery
- lead optimization
- cardiovascular disease
- macular degeneration
- neurological disorders
- infectious disease